Publication Name	World Journal of Hepatology
Manuscript ID	20003
Country	Italy

Received	2015-05-27 15:49
Peer-Review Started	2015-05-29 13:36
To Make the First Decision	2015-07-27 18:38
Return for Revision	2015-08-01 18:25
Revised	2015-08-14 03:26
Second Decision	2015-09-10 08:19
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-09-18 14:11
Articles in Press	2015-09-18 14:11
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-09-20 15:09
Publish the Manuscript Online	2015-10-02 19:06

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	All-oral interferon-free treatments: The end of hepatitis C virus story, the dream and the reality
Manuscript Source	Invited Manuscript
All Author List	Luigi E Adinolfi and Barbara Guerrera
Funding Agency and Grant Number
Corresponding Author	Luigi E Adinolfi, MD, Professor, Director, Department of Medical, Surgical, Neurological, Geriatric and Metabolic Sciences, Second University of Naples, ASL Caserta, Rione Santella, 80100 Naples, Italy. luigielio.adinolfi@unina2.it
Key Words	Sofosbuvir; Simeprevir; New-oral hepatitis C virus treatments; Paritaprevir; Dasabuvir; Daclatasvir; Ledipasvir; Ombitasvir
Core Tip	It is begun the era of all-oral direct-acting antiviral drugs for hepatitis C virus (HCV) treatment allowing interferon-free therapeutic regimens. These regimens are safe and yield cure rate greater than 90%. The therapeutic success has posed the basis for HCV elimination, although, confirmation are waiting from real world. However, many conditions hinder the fulfillment of the dream. These conditions are the excessive cost of drugs, the access and delivery of care, the epidemiology of HCV and the political commitments. Thus, an urgent effort must be done to make accessible on large-scale all-oral anti-HCV therapies allowing saving millions of lives.
Publish Date	2015-10-02 19:06
Citation	Adinolfi LE, Guerrera B. All-oral interferon-free treatments: The end of hepatitis C virus story, the dream and the reality. World J Hepatol 2015; 7(22): 2363-2368
URL	http://www.wjgnet.com/1948-5182/full/v7/i22/2363.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i22.2363

Full Article (PDF)	WJH-7-2363.pdf
Full Article (Word)	WJH-7-2363.doc
Manuscript File	20003-Review.docx
Answering Reviewers	20003-Answering reviewers.pdf
Audio Core Tip	20003-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	20003-Conflict-of-interest statement.pdf
Copyright License Agreement	20003-Copyright assigniment.pdf
Non-Native Speakers of English Editing Certificate	20003-Language certificate.pdf
Peer-review Report	20003-Peer-review(s).pdf
Scientific Misconduct Check	20003-Scientific misconduct check.pdf
Scientific Editor Work List	20003-Scientific editor work list.pdf